{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"pseudohypoparathyroidism-type-2","columns":[{"gene":"","key":"population-fa94a506e9ebc19c1476","label":"Pseudohypoparathyroidism, type II","mondoId":"MONDO:0008749","onsetQualifier":null,"originColumnKey":"MONDO:0008749/OMIM:203330","originalViews":[{"key":"MONDO:0008749/OMIM:203330","label":"Pseudohypoparathyroidism, type II","scopeLabel":"OMIM:203330","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["0a6970cbbdba2eefcc4c5b479d1e79ca31dab1293267a93ae918ab39608eb502","31f2ddde5f545c8638655eb032910a9180b91430deb03fa2972caf2c6aa25744","bae33141b0dce608a8717e93f7412567d6821a086f199b7149084f2424c627af","fc5c8c5f4ba3f0ce150564dfb6f2300b67bfc0189199d6bb99671c6736949f32"],"recordQualifiers":{},"scopeLabel":"OMIM:203330","sourceIds":["OMIM:203330"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"population-498588a8d95dd8ac6da7","label":"Pseudohypoparathyroidism type 2","mondoId":"MONDO:0008749","onsetQualifier":null,"originColumnKey":"MONDO:0008749/ORPHA:94090","originalViews":[{"key":"MONDO:0008749/ORPHA:94090","label":"Pseudohypoparathyroidism type 2","scopeLabel":"ORPHA:94090","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["133865bef9d66ae93790de8f0dc8a9fd176f16df7a4cb253bbdf79ddd6b58df6","168c7e7e4bf380e7242213aa24cb63f0abde64d99ae2d8d3f8a1b1d15740df1c","17b181ec707a716d320b0c8e9933a7705a549f531e7c2a3249a65e3a235bd8ba","298fab75b5b0a44bf1a432a1a6d7041c882b2282b512cc41fa4025d477192a25","2cafd4dc52e28573b65c9316ef78f169f57e159606c135f4424b0f55568c90c1","3500433bc5706e93e0c7cccdfccb8dc2f4a0aa65e26492abe5a21fc91693e591","528acca715484938fcdb7b483e6de6400d18671e5b77069095671d20b8e2539f","6a5f8f075e06c61e2da1b82a35172bec94b29634b17f357dd2b8d6577774d19d","76d4ac2c5f38df8e466b3708ca2e5bfa0848d808f9dd9ef32345ce5f79e1f2d7","950b59c54ba4ae4d0f4070994cbd3d49c696bf37a58420e3924c68ba86185501","c6920aa46bb53ba0d44ba353baad58cb0f02ab492f63318676addce59a8dc30a","d22ba36c18d1790d29daf926b84a78bfbaf5785225a833720349c4868461512a","de6bc928576ea47d57745c520b97fb9123bd9a6b305ad41a052acb2d3fde2670","ec3ccc90dd74b82e0d970bba95a1c32a88053e0d5db44ea0c8c995917c3eeab4","ec99712e2ba327c4469e919a8a0f5266affcf6861234915a6fe5f993fdf911a4","f0fd8ad1a5acadacbf2d35236ce56aae1332b519c3ddcb9238363fecf4f33683"],"recordQualifiers":{},"scopeLabel":"ORPHA:94090","sourceIds":["ORPHA:94090"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-fa94a506e9ebc19c1476","population-498588a8d95dd8ac6da7"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0011458","HP:0030057","HP:0003761","HP:0010766","HP:0003165","HP:0002905","HP:0002901"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":20,"sourceGroups":{"omim":4,"orphanet":16}},"features":[{"hpoId":"HP:0011458","label":"Abdominal symptom","primary":true},{"hpoId":"HP:0030057","label":"Autoimmune antibody positivity","primary":true},{"hpoId":"HP:0003761","label":"Calcinosis","primary":true},{"hpoId":"HP:0010766","label":"Ectopic calcification","primary":true},{"hpoId":"HP:0003165","label":"Elevated circulating parathyroid hormone level","primary":true},{"hpoId":"HP:0002905","label":"Hyperphosphatemia","primary":true},{"hpoId":"HP:0002901","label":"Hypocalcemia","primary":true},{"hpoId":"HP:0002199","label":"Hypocalcemic seizures","primary":false},{"hpoId":"HP:0003472","label":"Hypocalcemic tetany","primary":false},{"hpoId":"HP:0012049","label":"Laryngeal dystonia","primary":false},{"hpoId":"HP:0003456","label":"Low urinary cyclic AMP response to PTH administration","primary":false},{"hpoId":"HP:0003394","label":"Muscle spasm","primary":false},{"hpoId":"HP:0003739","label":"Myoclonic spasms","primary":false},{"hpoId":"HP:0003401","label":"Paresthesia","primary":false},{"hpoId":"HP:0001657","label":"Prolonged QT interval","primary":false},{"hpoId":"HP:0000852","label":"Pseudohypoparathyroidism","primary":false}],"ledeHtml":"Pseudohypoparathyroidism type 2 (PHP2) is a type of pseudohypoparathyroidism (PHP) characterized by resistance to parathyroid hormone (PTH), which manifests with hypocalcemia, hyperphosphatemia and elevated PTH levels, absence of Albright&#x27;s hereditary osteodystrophy (AHO), and normal expression of the Gs protein with a normal urinary cAMP response.","mondoId":"MONDO:0008749","node":{"canonicalSlug":"pseudohypoparathyroidism-type-2","comparisons":[{"documentSha256":"17a19b4e850f5bc8ad81ac1ae3b7cda8fbb2d482e13ae22cb7d47ce3dfa36658","key":"legacy-pseudohypoparathyroidism","kind":"legacy","label":"pseudohypoparathyroidism","memberIds":["MONDO:0007078","MONDO:0008749","MONDO:0011301","MONDO:0012912","MONDO:0019992"],"mondoId":"MONDO:0019992","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/pseudohypoparathyroidism.17a19b4e850f5bc8ad81ac1ae3b7cda8fbb2d482e13ae22cb7d47ce3dfa36658.json"},{"documentSha256":"f830cfc10b3f25d5a76574a14f521c54ab0c0a0ba342f44b461714af68527c5a","key":"expanded-pseudohypoparathyroidism","kind":"expanded","label":"pseudohypoparathyroidism","memberIds":["MONDO:0007078","MONDO:0008749","MONDO:0011301","MONDO:0012911","MONDO:0012912","MONDO:0019992"],"mondoId":"MONDO:0019992","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-f830cfc10b3f25d5a765.f830cfc10b3f25d5a76574a14f521c54ab0c0a0ba342f44b461714af68527c5a.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"pseudohypoparathyroidism type 2","paragraphs":["Pseudohypoparathyroidism type 2 (PHP2) is a type of pseudohypoparathyroidism (PHP) characterized by resistance to parathyroid hormone (PTH), which manifests with hypocalcemia, hyperphosphatemia and elevated PTH levels, absence of Albright's hereditary osteodystrophy (AHO), and normal expression of the Gs protein with a normal urinary cAMP response."],"scope":"exact","source":"MONDO","upstream":"Orphanet:94090","url":"https://monarchinitiative.org/MONDO:0008749"},"ownColumnKeys":["population-fa94a506e9ebc19c1476","population-498588a8d95dd8ac6da7"],"publication":"published","relationships":[{"kind":"parent","label":"pseudohypoparathyroidism","mondoId":"MONDO:0019992","slug":"pseudohypoparathyroidism"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Name scope not exact or reviewed","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/10682"}],"translation":"published"},"records":[{"frequencyKind":"reported","key":"0a6970cbbdba2eefcc4c5b479d1e79ca31dab1293267a93ae918ab39608eb502","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:203330","disease_name":"Pseudohypoparathyroidism, type II","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003165","is_excluded":false,"label":"Elevated circulating parathyroid hormone level","onset_id":null,"reference":"OMIM:203330","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"133865bef9d66ae93790de8f0dc8a9fd176f16df7a4cb253bbdf79ddd6b58df6","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0030057","is_excluded":true,"label":"Autoimmune antibody positivity","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"168c7e7e4bf380e7242213aa24cb63f0abde64d99ae2d8d3f8a1b1d15740df1c","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003472","is_excluded":false,"label":"Hypocalcemic tetany","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"17b181ec707a716d320b0c8e9933a7705a549f531e7c2a3249a65e3a235bd8ba","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003739","is_excluded":false,"label":"Myoclonic spasms","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"298fab75b5b0a44bf1a432a1a6d7041c882b2282b512cc41fa4025d477192a25","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0003761","is_excluded":true,"label":"Calcinosis","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2cafd4dc52e28573b65c9316ef78f169f57e159606c135f4424b0f55568c90c1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003401","is_excluded":false,"label":"Paresthesia","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"31f2ddde5f545c8638655eb032910a9180b91430deb03fa2972caf2c6aa25744","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:203330","disease_name":"Pseudohypoparathyroidism, type II","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002905","is_excluded":false,"label":"Hyperphosphatemia","onset_id":null,"reference":"OMIM:203330","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"3500433bc5706e93e0c7cccdfccb8dc2f4a0aa65e26492abe5a21fc91693e591","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0000852","is_excluded":false,"label":"Pseudohypoparathyroidism","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"528acca715484938fcdb7b483e6de6400d18671e5b77069095671d20b8e2539f","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0010766","is_excluded":true,"label":"Ectopic calcification","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"6a5f8f075e06c61e2da1b82a35172bec94b29634b17f357dd2b8d6577774d19d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0003456","is_excluded":true,"label":"Low urinary cyclic AMP response to PTH administration","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"76d4ac2c5f38df8e466b3708ca2e5bfa0848d808f9dd9ef32345ce5f79e1f2d7","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003394","is_excluded":false,"label":"Muscle spasm","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"950b59c54ba4ae4d0f4070994cbd3d49c696bf37a58420e3924c68ba86185501","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001657","is_excluded":false,"label":"Prolonged QT interval","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"bae33141b0dce608a8717e93f7412567d6821a086f199b7149084f2424c627af","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:203330","disease_name":"Pseudohypoparathyroidism, type II","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000852","is_excluded":false,"label":"Pseudohypoparathyroidism","onset_id":null,"reference":"OMIM:203330","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"c6920aa46bb53ba0d44ba353baad58cb0f02ab492f63318676addce59a8dc30a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002901","is_excluded":false,"label":"Hypocalcemia","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d22ba36c18d1790d29daf926b84a78bfbaf5785225a833720349c4868461512a","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003165","is_excluded":false,"label":"Elevated circulating parathyroid hormone level","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"de6bc928576ea47d57745c520b97fb9123bd9a6b305ad41a052acb2d3fde2670","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0012049","is_excluded":false,"label":"Laryngeal dystonia","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ec3ccc90dd74b82e0d970bba95a1c32a88053e0d5db44ea0c8c995917c3eeab4","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002905","is_excluded":false,"label":"Hyperphosphatemia","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ec99712e2ba327c4469e919a8a0f5266affcf6861234915a6fe5f993fdf911a4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002199","is_excluded":false,"label":"Hypocalcemic seizures","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f0fd8ad1a5acadacbf2d35236ce56aae1332b519c3ddcb9238363fecf4f33683","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:94090","disease_name":"Pseudohypoparathyroidism type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0011458","is_excluded":false,"label":"Abdominal symptom","onset_id":null,"reference":"ORPHA:94090","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"fc5c8c5f4ba3f0ce150564dfb6f2300b67bfc0189199d6bb99671c6736949f32","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:203330","disease_name":"Pseudohypoparathyroidism, type II","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002901","is_excluded":false,"label":"Hypocalcemia","onset_id":null,"reference":"OMIM:203330","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0008749\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:94090</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Pseudohypoparathyroidism type 2 (PHP2) is a type of pseudohypoparathyroidism (PHP) characterized by resistance to parathyroid hormone (PTH), which manifests with hypocalcemia, hyperphosphatemia and elevated PTH levels, absence of Albright&#x27;s hereditary osteodystrophy (AHO), and normal expression of the Gs protein with a normal urinary cAMP response.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0008749\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"pseudohypoparathyroidism-type-2","sourceDocuments":[{"name":"MONDO: pseudohypoparathyroidism type 2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0008749"}],"sourceNote":"","synonyms":["PHP II","PHP2","pseudohypoparathyroidism, type II"],"takeawayHtml":"","title":"pseudohypoparathyroidism type 2"},"schemaVersion":1}
